1.39

1.82% 0.02

Pacific Biosciences Of California Inc (PACB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché PACB Giù? Forum Previsione

Precedente Chiudi:

$1.37

Aprire:

$1.38

Volume 24 ore:

1.08M

Relative Volume:

0.15

Capitalizzazione di mercato:

$421.29M

Reddito:

$188.87M

Utile/perdita netta:

$-400.38M

Rapporto P/E:

-0.9267

EPS:

-1.5

Flusso di cassa netto:

$-260.90M

1 W Prestazione:

-10.58%

1M Prestazione:

-24.18%

6M Prestazione:

+10.71%

1 anno Prestazione:

+6.49%

Intervallo 1D:

$1.36

$1.41

Intervallo di 1 settimana:

$1.32

$1.565

Portata 52W:

$0.8511

$2.73

Pacific Biosciences Of California Inc Stock (PACB) Company Profile

Nome

Pacific Biosciences Of California Inc

Settore

Healthcare (1117)

Industria

Medical Devices (139)

Telefono

650-521-8000

Indirizzo

1305 O'BRIEN DRIVE, MENLO PARK, CA

Dipendente

485

Cinguettio

@pacbio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

PACB's Discussions on Twitter

Compare PACB vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PACB Pacific Biosciences Of California Inc	1.395	413.74M	188.87M	-400.38M	-260.90M	-1.50
ABT Abbott Laboratories	110.15	192.10B	44.33B	6.50B	7.40B	3.717
SYK Stryker Corp	350.82	137.25B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	89.36	115.41B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	68.51	103.81B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	85.22	49.82B	6.07B	1.06B	1.34B	1.8063

Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-06	Downgrade	Barclays	Equal Weight → Underweight
2024-11-11	Downgrade	UBS	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Buy
2024-04-22	Downgrade	JP Morgan	Overweight → Neutral
2024-04-18	Downgrade	Goldman	Buy → Neutral
2023-12-14	Iniziato	Guggenheim	Neutral
2023-12-14	Iniziato	Stephens	Overweight
2023-12-13	Iniziato	Wolfe Research	Peer Perform
2023-11-17	Aggiornamento	UBS	Neutral → Buy
2023-10-31	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2023-09-28	Iniziato	Bernstein	Outperform
2023-07-05	Ripresa	JP Morgan	Overweight
2023-06-30	Iniziato	Goldman	Buy
2023-05-10	Iniziato	Barclays	Equal Weight
2023-03-31	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-02-02	Iniziato	UBS	Neutral
2023-01-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-21	Ripresa	Cantor Fitzgerald	Overweight
2022-01-06	Ripresa	Piper Sandler	Neutral
2021-10-15	Ripresa	Cowen	Market Perform
2021-09-27	Iniziato	Canaccord Genuity	Buy
2021-02-11	Aggiornamento	Piper Sandler	Neutral → Overweight
2020-11-03	Downgrade	Piper Sandler	Overweight → Neutral
2020-10-02	Aggiornamento	JP Morgan	Neutral → Overweight
2020-09-09	Iniziato	Morgan Stanley	Equal-Weight
2020-06-02	Ripresa	Cantor Fitzgerald	Overweight
2020-03-09	Ripresa	Cantor Fitzgerald	Overweight
2019-10-15	Aggiornamento	Piper Jaffray	Neutral → Overweight
2019-04-02	Downgrade	Stephens	Overweight → Equal-Weight
2018-10-19	Iniziato	Cowen	Outperform
2017-11-03	Downgrade	First Analysis Sec	Overweight → Equal-Weight
2017-09-28	Downgrade	CL King	Buy → Neutral
2016-11-03	Reiterato	Cantor Fitzgerald	Buy
2016-06-27	Iniziato	CL King	Buy
2016-04-15	Iniziato	First Analysis Sec	Overweight
2016-02-04	Downgrade	Piper Jaffray	Overweight → Neutral
2016-01-04	Reiterato	Cantor Fitzgerald	Buy
2015-10-23	Aggiornamento	Piper Jaffray	Neutral → Overweight
2015-08-27	Iniziato	Cantor Fitzgerald	Buy
2015-02-04	Reiterato	Maxim Group	Buy
2013-09-26	Reiterato	Maxim Group	Buy
2013-01-14	Reiterato	Maxim Group	Buy

Mostra tutto

Pacific Biosciences Of California Inc Borsa (PACB) Ultime notizie

Mar 09, 2026

Why The PacBio (PACB) Investment Story Is Shifting As Analysts Cut Targets And Flag Risks - Yahoo Finance

Mar 09, 2026

HiFi sequencing enables automatic detection of 5mC and 6mA, Pacific Biosciences of California asserts - Traders Union

Mar 09, 2026

Mar 06, 2026

Pacific Biosciences Secures Key Patent License, Ends Litigation - TipRanks

Mar 06, 2026

Pacific Biosciences announces accounting officer transition and litigation settlement - Investing.com

Mar 06, 2026

PACB - Finviz

Mar 06, 2026

PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know - Finviz

Mar 06, 2026

PACB Analyst Rating Downgrade by Barclays to Underweight | PACB Stock News - GuruFocus

Mar 06, 2026

Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays - MarketBeat

Mar 06, 2026

Barclays downgrades Pacific Biosciences stock rating on catalysts By Investing.com - Investing.com Canada

Mar 06, 2026

Barclays downgrades Pacific Biosciences stock rating on catalysts - Investing.com UK

Mar 06, 2026

PacBio Announces the Appointment of Chris Gibson to the Board of Directors - Sahm

Mar 06, 2026

Mar 05, 2026

Pacific Biosciences of California unveils HiFi sequencing for comprehensive multiomic analysis - Traders Union

Mar 05, 2026

PacbBio Announces Appointment of Christopher Gibson to Board of Directors and Member of the Science and Technology Committee, Effective March 3, 2026 - marketscreener.com

Mar 05, 2026

PacBio Adds AI-Driven Drug Discovery Leader to Board - TipRanks

Mar 05, 2026

Pacbio announces the appointment of Chris Gibson to the board of directors - marketscreener.com

Mar 05, 2026

PacBio Appoints New Board Member - Intellectia AI

Mar 05, 2026

AI drug discovery founder from Recursion joins PacBio board - Stock Titan

Mar 05, 2026